35例绝经后乳腺癌新辅助内分泌治疗近期疗效临床分析

Short-term Observiation on Neoadjuvant Endocrine Therapy of Postmenopausal Breast Cancer in 35 patients

目的:探讨绝经后乳腺癌术前新辅助内分泌治疗的近期疗效。方法:35例老年乳腺癌患者术前服用芳香化酶抑制剂4～9个月后进行手术。结果:术前内分泌治疗,完全缓解2例(5.7%),部分缓解27例(77.1%),无变化3例(8.6%),进展3例(8.6%)。结论:绝经后、ER(+)乳腺癌病人采用来曲唑治疗有效、安全、可靠,为缩小手术切除术式创造条件,尤对年迈、体弱、和并其他严重疾病患者很好的治疗选择。

Objective：To evaluate the short-term offects of neoadjuvant endocrin,therapy（NET）on postmenopausal breast cancer patients Methods： Thirty five case of postmenopausal breast cancer patients with stage Ⅱand Ⅲ were lreated with letrozole for 4 months before operation. Results： Preoperative neoadjuvant endocrin, therapy,complete remission 2 patients（5.7 %）, partial remission 27 patients（77.1% ）no change 3 patients（8.6%）, progression 3patients（8.6%）. Conclusion： NET with letrozole as a treatment option for pnstmenopausal patiems with receptor-positiv breast cancer might effective and safe, especially for ehterly women who cannot tolerat the toxicities of chemotherapy or concomitant with some serious diseases who are no eligible for radical mastectomy.